|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||244.76 - 248.54|
|52 Week Range||191.53 - 248.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 2, 2018|
|Forward Dividend & Yield||3.00 (1.24%)|
|1y Target Est||256.47|
Becton, Dickinson's (BDX) core BD Medical likely to register solid results in Q3; a possible decline in BD Life Sciences raises concern.
Becton Dickinson’s (BDX) life sciences segment generated revenues of $1.1 billion in the second quarter of 2018, reflecting ~7.3% year-over-year (or YoY) growth on a currency neutral basis. Becton Dickinson’s life science segment reported revenues of $2.1 billion in the first half of 2018, reflecting ~7.3% YoY growth.
In the second quarter of 2018, Becton Dickinson’s (BDX) Medical segment generated revenues of $2.2 billion, reflecting ~4.2% year-over-year (or YoY) growth on a currency-neutral basis. Becton Dickinson’s Medical segment reported revenues of $4.0 billion during the first half of 2018, reflecting ~1.6% YoY growth.
FRANKLIN LAKES, N.J. , July 12, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2017 Sustainability Performance Update ...
Becton Dickinson (BDX) generated revenues $4.2 billion in the second quarter of 2018 compared to $3.0 billion in the second quarter of 2017, reflecting ~42.2% year-over-year growth. The acquisition of CR Bard was primarily attributed to the steep growth in Becton Dickinson’s revenues.
On July 9, Becton Dickinson (BDX) announced its acquisition of TVA Medical. TVA Medical is a technology company focused on the development of minimally invasive vascular access solutions for individuals with chronic kidney diseases who require dialysis. The acquisition of TVA Medical allows Becton Dickinson to add everlinQ endoAVF System, an endovascular arteriovenous fistula creation technology, to its product portfolio.
The acquisition of TVA Medical will enable Becton, Dickinson (BDX) to treat patients with chronic kidney disease through minimally invasive procedures.
On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: Becton, Dickinson and Co. (NYSE: BDX), Ekso Bionics Holdings Inc. (NASDAQ: EKSO), Haemonetics Corp. (NYSE: HAE), and Hologic Inc. (NASDAQ: HOLX).
The project along Tempe Town Lake is geared toward new technology companies, and the city is trying to lure in tenants.
Evercore ISI analyst Vijay Kumar has named Becton, Dickinson and Co. The three months ended June 30, BD's third fiscal quarter for 2018, is the "first clean [quarter] without any adjustments for US dispensing change / flu noise," Kumar wrote in a note on Monday, July 9. Franklin Lakes, N.J.-based BD is scheduled to release results on Aug. 2.
With annual revenue of more than $12 billion and about 65,000 employees, Becton Dickinson is one of the biggest players in the medical-device world. It now owns the assets of a promising Austin company.
FRANKLIN LAKES, N.J., July 9, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced it has completed the acquisition of TVA Medical, Inc., a company that develops minimally invasive vascular access solutions for patients with chronic kidney disease requiring hemodialysis. In the U.S. alone, there are more than 440,000 patients with End-Stage Renal Disease (ESRD) who are surviving on hemodialysisi. The addition of TVA Medical enables BD to offer the everlinQ™ endoAVF System, a new endovascular arteriovenous (AV) fistula creation technology that adds to the company's ESRD portfolio of dialysis catheters, drug coated balloons, standard angioplasty balloons and endovascular stent graft products.
FRANKLIN LAKES, N.J. , July 5, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2018 earnings conference ...
Does the share price for Becton Dickinson and Company (NYSE:BDX) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value by projecting its future cash flows and thenRead More...
With Bard being assimilated into Becton Dickinson for about two quarters now, the latter is likely to outperform the Street's top- and bottom-line expectations for the second half of 2018 as well as fiscal 2019, Marcus said in a Thursday note. Becton Dickinson will benefit from neutral pricing, with upside opportunity being found in more aggressive price capture.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health toRead More...
Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health
Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as Becton Dickinson and Company (NYSE:BDX) a safer option. Risk-averse investors who are attracted to diversifiedRead More...